Anti-Somatostatin 28 antibody [EPR3360(2)]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Somatostatin 28 also known as SST-28 is a biologically active peptide that functions as a hormone. It is an alternate form of somatostatin the other being somatostatin-14. Somatostatin 28 is characterized by its longer peptide chain with a molecular mass of approximately 3.2 kDa. This peptide is expressed mainly in the central nervous system particularly in the hypothalamus and in the gastrointestinal tract. Its synthesis involves specific posttranslational processing steps and it acts in various cellular locations performing regulatory roles in endocrine and exocrine systems.

Biological function summary

Somatostatin 28 plays an important role in inhibiting the release of certain hormones and neurotransmitters. It exerts its effects by binding to specific somatostatin receptors which are part of a family of G-protein-coupled receptors. These receptors when activated by somatostatin 28 can inhibit adenylyl cyclase activity reducing cyclic AMP levels and therefore suppressing hormone secretion. While somatostatin 28 does not form part of a large multi-protein complex it acts collaboratively with related peptides and receptors to modulate neuronal and digestive functions.

Pathways

Somatostatin 28 participates centrally in the regulation of the endocrine signaling pathways notably influencing the growth hormone inhibitory pathway. This pathway involves interconnected proteins such as growth hormone-releasing hormone (GHRH) which somatostatin 28 suppresses. Additionally the peptide plays a role in modulating the insulin signaling pathway where it inhibits the secretion of insulin. These pathways highlight somatostatin 28's regulatory influence on metabolism and cellular growth by interacting with other proteins like insulin and GHRH.

Associated diseases and disorders

Somatostatin 28 is implicated in conditions such as acromegaly and certain types of diabetes. In acromegaly excessive growth hormone production often due to pituitary adenomas is counteracted by somatostatin 28's inhibitory effects. The peptide's interaction with the receptor-bound growth hormone contributes to potential therapeutic approaches to managing this disorder. In diabetes specifically type 2 somatostatin 28's role in inhibiting insulin release provides insight into its involvement in glucose metabolism dysregulation. Understanding these connections highlights the importance of somatostatin 28 and related proteins like insulin in the pathophysiology of metabolic diseases.